Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Cipla Not Ready For U.S. Biosimilars Market Even As Peers Line Up For Bigger Piece Of Pie

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Cipla - India's largest drug maker by market share - will not be amongst the first bunch of companies that prepare to launch biosimilars in the U.S

You may also be interested in...



On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era

The health care reform legislation signed into law by President Obama March 23 paves the way for the launch of biosimilar drugs in the U.S., action that could save the country's health care system billions of dollars, while presenting both challenges and opportunities for the drug industry

Indian Court Says "No" To Linking Patents With Regulatory Approvals; Sends Back Six Patent Oppositions

MUMBAI - In two back-to-back judgments delivered by the Delhi High Court this week, multinational drug companies Bayer and Eli Lilly suffered major setbacks as the Indian court rejected their separate pleas - one related to the linkage of patent grants with regulatory approvals and the other a re-examination of the existing system for patent oppositions

India's Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10

HYDERABAD, India - Enthused by the success of its first monoclonal antibody Reditux - a copy of Genentech's Rituxan (rituximab) - India's Dr. Reddy's Labs is making a full throttle attempt to develop and launch copies of most blockbuster biotech drugs available in the international markets

Related Content

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel